Issued shares

Canadian Premium Sand Inc. Announces Closing of Upsized $5.2 Million Non-Brokered Private Placement

Retrieved on: 
Wednesday, June 16, 2021
Stock market, Financial economics, Corporate finance, Finance, Money, Initial public offering, Prospectus, Issued shares, Equity securities

After giving effect to the Offering, the Company will have 42,043,660 common shares issued and outstanding.

Key Points: 
  • After giving effect to the Offering, the Company will have 42,043,660 common shares issued and outstanding.
  • The Corporations two significant shareholders and certain directors and officers participated in the Offering.
  • On a combined basis they subscribed for an aggregate of 8,330,700 Common Shares for $2,082,675.
  • The Common Shares were distributed in certain Canadian jurisdictions in reliance upon exemptions set forth in National Instrument 45-106 - Prospectus Exemptions.

Renesas Announces Determination of Number of New Shares to be Issued and Number of Shares to be Sold

Retrieved on: 
Friday, June 11, 2021
Electronic design automation, Semiconductor, Automotive, General Automotive, Technology, Hardware, Corporate finance, Financial markets, Financial economics, Finance, Stock market, Renesas Electronics, Stock, Issued shares, Public offering, Offering, Initial public offering, Preferred stock

36,373,600 shares of common stock of Renesas to be underwritten and purchased by the Japanese underwriters in the Japanese Public Offering.

Key Points: 
  • 36,373,600 shares of common stock of Renesas to be underwritten and purchased by the Japanese underwriters in the Japanese Public Offering.
  • 145,494,200 shares of common stock of Renesas to be underwritten and purchased by the international managers in the International Offering.
  • 123,761,800 shares of common stock of Renesas to be underwritten and purchased by the international managers in the International Secondary Offering.
  • Current total number of issued shares:
    Number of shares to be increased by the issuance of new shares through the Japanese Public Offering and the International Offering:
    Total number of issued shares after the issuance of new shares through the Japanese Public Offering and the International Offering:
    As Renesas has issued stock acquisition rights, Current total number of issued shares refers to the total number of issued shares as of May 31, 2021.

BlackRock Science and Technology Trust Announces Terms of Rights Offering

Retrieved on: 
Wednesday, June 9, 2021
Professional services, Finance, Stock market, Corporate finance, Common law, Equity, Inheritance, Trust law, Corporations, Issued shares, Articles, Economy

BlackRock Science and Technology Trust (NYSE: BST) (the "Trust") today announced that its Board of Trustees (the "Board") has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Trust's common shares of beneficial interest (par value $0.001 per share) ("Shares") as of June 18, 2021 (the "Record Date").

Key Points: 
  • BlackRock Science and Technology Trust (NYSE: BST) (the "Trust") today announced that its Board of Trustees (the "Board") has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Trust's common shares of beneficial interest (par value $0.001 per share) ("Shares") as of June 18, 2021 (the "Record Date").
  • Holders of Rights will be entitled to subscribe for additional Shares (the "Offer") at a discount to the market price of the Shares.
  • The Trust expects to maintain its current distribution level following the Offer.
  • Shares issued pursuant to the Offer will be entitled to receive the monthly distribution expected to be payable in August.

SThree: Issue of Shares

Retrieved on: 
Tuesday, June 8, 2021
Corporate finance, Financial economics, Finance, Stock market, Equity securities, Money, Corporate law, Issued shares, Common stock, Share, Public limited company

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • SThree plc announces that today it issued 1,402 new Ordinary shares of 1p each.
  • For confirmation, the Company's issued capital is now 133,490,111 Ordinary shares of 1p each.
  • Following this issue, the total number of voting rights in SThree is 133,454,344 ordinary shares of 1p each and there are 35,767 shares held in treasury.

FAX Capital Corp. Announces Renewal of Normal Course Issuer Bid

Retrieved on: 
Friday, June 4, 2021
Financial markets, Stock market, Financial economics, Finance, Corporate finance, Equity securities, Share, Issued shares, Initial public offering

As at May 31, 2021, the Company had 15,812,608 Subordinate Voting Shares issued and outstanding and a public float of 14,884,805 Subordinate Voting Shares.

Key Points: 
  • As at May 31, 2021, the Company had 15,812,608 Subordinate Voting Shares issued and outstanding and a public float of 14,884,805 Subordinate Voting Shares.
  • The price that the Company will pay for any such Subordinate Voting Shares will be the market price of such shares at the time of acquisition.
  • The Company may, however, complete one block purchase per calendar week that exceeds the Daily Limit in accordance with TSX rules.
  • Under the Previous NCIB, the Company obtained the approval of the TSX to purchase up to 1,519,037 Subordinate Voting Shares for cancellation.

Novo Integrated Sciences Enters into Share Exchange Agreement to Acquire Acenzia Inc.

Retrieved on: 
Thursday, June 3, 2021
Managed care, General Health, Pharmaceutical, Health, Stock market, Corporate finance, Financial economics, Finance, Money, Corporate law, Issued shares, Preferred stock

Upon closing the share exchange, Acenzia will be a wholly owned subsidiary of NHL and the Acenzia shareholders will receive NHL non-voting exchangeable preferred shares issued solely for the purpose to exchange for allotted restricted shares of the Companys common stock at a per share price of $3.91.

Key Points: 
  • Upon closing the share exchange, Acenzia will be a wholly owned subsidiary of NHL and the Acenzia shareholders will receive NHL non-voting exchangeable preferred shares issued solely for the purpose to exchange for allotted restricted shares of the Companys common stock at a per share price of $3.91.
  • Robert Mattacchione, the Companys CEO and Board Chairman, stated, There are three primary pillars in support of Novos business model centered on decentralized healthcare.
  • Innovation in science as represented by the proprietary technology possessed by Acenzia assures Novo of continued cutting edge advancement in patient first platforms.
  • For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com .

Eve Sleep plc: Total Voting Rights

Retrieved on: 
Wednesday, June 2, 2021
Financial economics, Corporate finance, Finance, Stock market, Equity securities, Corporations, Corporate law, Common stock, Issued shares, Share

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with the Disclosure Guidance and Transparency Rule 5.6.1, the Company notifies the market of the following: as at 31 May 2021, the total issued share capital of the Company comprised 274,085,479 ordinary shares of 0.1 pence each ("Ordinary Shares") with one voting right per share.
  • The Company does not hold any Ordinary Shares in Treasury.

Rise Capital Corp. Early Warning Reporting – Acquisition of Rise Capital Corp. Shares

Retrieved on: 
Wednesday, June 2, 2021
Corporate finance, Stock market, Finance, Financial economics, Money, Corporate law, Equity securities, Fundamental analysis, Shares outstanding, Share, Issued shares

Prior to the Offering, the Acquiror beneficially owned 2,000,001 Shares, representing approximately 20.00001% of the Corporation's issued and outstanding Shares.

Key Points: 
  • Prior to the Offering, the Acquiror beneficially owned 2,000,001 Shares, representing approximately 20.00001% of the Corporation's issued and outstanding Shares.
  • On May 26, 2021, The Acquiror acquired beneficial ownership of 4,000,000 Shares, which resulted in the cumulative acquisition of 6,000,001 Shares, representing approximately 10.91% of the Shares issued and outstanding immediately after the completion of the Offering, thereby triggering the requirement to file an early warning report under NI 62-103.
  • A copy of the early warning report filed by the Acquiror will be available on the Company's SEDAR profile at www.sedar.com or may be obtained by contacting Michael Zych at (905) 825-4011.
  • The Company's head office is located 20 Holly Street, Suite 300, Toronto, Ontario, M4S 3B1.

SThree: Voting Rights and Capital

Retrieved on: 
Tuesday, June 1, 2021
Stock market, Corporate law, Finance, Financial economics, Money, Corporate finance, Sthree, Issued shares, Issuer, Insider trading, Share capital

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • At the date of this announcement, SThree plc's issued share capital consists of 133,488,709 ordinary shares of 1p each.
  • Currently there are 35,767 shares held in Treasury, and the total number of voting rights in SThree plc is 133,452,942.

Total Voting Rights

Retrieved on: 
Tuesday, June 1, 2021
Corporate finance, Corporate law, Financial economics, Corporations, Finance, Stock market, Equity securities, Issued shares, Common stock, Share capital

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • In conformity with 5.6.1R of the Disclosure Guidance and Transparency Rules, Arix Bioscience plc announces that its total issued share capital at the close of business on 28 May 2021 comprised 135,609,653 Ordinary Shares of 0.001 pence each fully paid.
  • This figure includes 3,592,853 Ordinary Shares which are held in Treasury, leaving a balance of 132,016,800 Ordinary Shares with voting rights.